Day 2

WELCOME COFFEE & REGISTRATION

CHAIR PERSON’S OPENING REMARKS

KEYNOTE PANEL: OPENING PANEL DISCUSSION: Increasing inclusion, diversity and equity in clinical research: Breaking down barriers to access

• Why diversity and inclusion in clinical trials are crucial?
• Understanding critical barriers to minority and underserved patient communities participation in clinical trials
• Actionable ways to improve diversity in clinical trials
• What can the industry do to promote more diversity in the future?
• Latest guidelines that make healthcare more inclusive

Fda's Patient Focused Drug Development: Incorporating patient voice in drug discovery and evaluation

• Incorporating robust and meaningful patient engagement for a more informed decision-making
• Strategies and best practices in facilitating patient recruitment and retention in clinical trials
• Enhance understanding and use appropriate methods to capture patient understanding of the benefits and risk outcomes
• How to best communicate patient information to support decision-making

KEYNOTE SESSION: Just putting patients at the centre of healthcare is not enough to improve care

• Major barriers to delivering patient-centred care
• Focus on scaling and spreading proven interventions
• Evidence to move forward and improve care for all patients, in all settings.

MORNING NETWORKING REFRESHMENTS

40 minutes Networking Refreshment Break. 

PLENARY SESSION: Next-generation digital innovation in Clinical trials

• Current trends in digital health technology that can improve clinical trial recruitment and retention
• Understanding patient needs to really make clinical trials accessible
• How to maximise the value of technology
• Digital innovation on the horizon

SPONSORED SPOTLIGHT: Access to the right data at the right time: Essential real-time data for more accurate and beneficial review

• The importance of data democratization
• Common challenges in clinical data review that hinders clinical trials
• Strategies in overcoming these challenges
• How to seamlessly integrate data from a variety of sources?
• How to improve safety review efficiencies and reduce the timeline to critical studies?

KEYNOTE PANEL: The Age of Advocacy: The importance of patient voice in the new normal

• What it takes to get it right and how to avoid common pitfalls
• Key priorities and opportunities for advocacy during COVID-19 and beyond
• New ways of thinking to ensure the industry remains a credible and valuable partner now and in the future
• Better collaboration between industry and patient organisations leads to improvements in patient care

NETWORKING LUNCH BREAK

1 Hour Networking Lunch Break, Follow by Round Table Discussions at 14:15 PM. 

ROUND TABLE DISCUSSIONS - divided between 2 sessions of 30 mins. (5 mins. to change table) - Attendees have 2 round table options to attend

TABLE 1: Advanced analytics and digital capabilities to promote better patient outcomes and an improvedreturn on investment (ROI).

TABLE 2: Design, Identification, and Sensitivity Analysis for Patient Preference Trials

TABLE 3: Enabling clients to be active on their own health care

TABLE 4: Societal perception of collaboration between patients, their organisations, and other stakeholders

TABLE 5: A value-based approached to patient engagement

AFTERNOON NETWORKING REFRESHMENT

40 minutes - Networking Refreshment Break at the Exhibitors Lounge Area.

Revolutionising the future of care through personalised healthcare

• A need to find a more personalised way of managing healthcare for each individual.
• Lessons learned in digital health from Covid-19
• Areas of opportunity to prioritise focus and resources for the most impact
• Enabling regulatory agility to provide greater personalised care

How to sustain a meaningful patient engagement across the lifecycle of medicines: A call for Action

• Innovations that are necessary for patient engagement to become a common practice
• Procedures that drive stakeholder alignment.
• Resources to mobilise human and financial means towards sustained patient engagement
• Tools for collaborative strategic planning that enables stakeholders to make strategies and take actions towards the desired future

CLOSING PANEL DISCUSSION: Driving patient-centric care during the COVID-19 Pandemic and beyond

• COVID-19 pandemic has highlighted the need for patient-centricity, understanding the drivers for innovation in pharma
• Partnering with patients and placing patient well-being at the core of all initiatives
  Shifting towards disease-oriented to patient-centric
• Innovative approaches for direct-to-patient assume significant importance for driving patient-centricity
• Technologies that enhance the patient-centricity in pharma

CHAIRPERSON’S CLOSING REMARKS

Thank you for your Participation at the Patient Centricity & Collaboration World Congress 2022 Americas.